Under 10% of individuals who could benefit from GLP-1 drugs including Wegovy are able to get them, caution the World Health Organization as it releases its inaugural advice on the medications.
Given in excess of 1,000,000,000 people worldwide currently obese, it is urging broader and more equitable availability to these injectable treatments.
Per estimates, more than two billion are projected to be obese by 2030 if no action is taken.
"The latest guidelines recognises that obesity is a lifelong illness that can be managed with thorough and continuous care," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are significant hurdles to broad access to the jabs that can assist patients in reducing substantial weight, says the body.
Skinny Jab Scarcity
Despite the present best projected outlook, the supply of these medications might only reach approximately 100 million people – under 10% of eligible patients, per the health organization.
The guideline encourages nations and manufacturers to widen availability, by strategies such as licensing agreements.
The intellectual property rights on the active ingredient – the main ingredient of a leading brand – is scheduled to end in multiple countries in 2026.
How Weight-Loss Injections Function
These medications imitate a natural hormone to slow digestion, suppress the appetite and increase the sense of being full so users consume fewer calories.
Patients commonly begin shedding pounds after several weeks of starting on the weekly injections.
Studies suggests patients may regain a significant portion within a year of discontinuing the treatment, when their usual food cravings return.
Being above a healthy weight increases your likelihood for developing diseases, such as type 2 diabetes, heart disease, brain attack, and some malignancies.
Excess weight concerns individuals in every country and was associated with over three and a half million deaths worldwide in 2024, per the WHO.
